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Detection of residual host ceils after bone marrow transplantation 
using non-isotopic in situ hybridization and karyotype analysis 
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Summary: 
Karyotype analysis and interphase cytogenetics by 
means of non-radioactive in situ hybridization (NISH) 
with Y and X-specific probes were used to detect 
residual host cells in B M of 18 male patients who had 
received a BMT from their sisters. All patients but one 
had a malignant blood disease; 17 patients were 
clinically in continuous remission at the time of the 
investigations and throughout the follow-up period. No 
host cells were detected by karyotype analysis in patients 
who were in clinical remission. NISH with a biotinylated 
Y-specific probe showed residual host cells in 16 of the 
17 patients in clinical remission. In samples from three 
patients the existence of host cells was further confirmed 
by revealing the XY-containing cells with two-color 
fluorescence in situ hybridization (FISH) using X- and 
Y-specific probes simultaneously. Hybridizations with a 
Y-specific probe on direct BM smears showed >3% 
residual host cells in 50% of the samples studied at or 
later than 2 months post-BMT. On conventional cyto-
genetic preparations <1% Y-specific cells were detected 
in all but two samples at ^2 months post-BMT. There 
was no difference in the proportion of host cells between 
patients conditioned with total body irradiation and C Y 
and those who received busulphan and C Y . The 
recipient's stromal or epithelial cells in the aspirates 
probably account for most of the host cells detected. In 
conclusion, small numbers of residual host cells detected 
by interphase cytogenetics with a Y-specific probe do 
not indicate an imminent relapse. Conventional cyto-
genetic preparations are preferable to direct smears in 
studying the presence of residual host hematopoietic 
cells because of probably less contamination by stromal 
cells. 
Allogeneic B M T following ablative chemo/radio-
therapy for the treatment of malignant blood disorders 
is expected to result in a full chimerism after hemato-
logic recovery. In recipients of sex-mismatch B M , 
karyotype analysis is often used to document the 
engraftment and to analyze the chimeric state of the 
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recipient after B M T . 1 2 By karyotype analyses, 
however, only proliferating cells that reach mitosis can 
be studied. Furthermore, only a small number of cells is 
usually analyzed. Thus, if residual host cells are present 
in low numbers or if these cells do not proliferate, they 
cannot be detected by routine cytogenetic methods. By 
including interphase cells in the analyses more accurate 
information about the presence and number of residual 
cells and their correlation, e.g. with conditioning 
regimen can be obtained. We 3 and others 4 , 5 have 
recently demonstrated that interphase cytogenetics 
with a Y-specific probe is a sensitive method for 
documenting the presence of residual host cells in the 
B M after BMT. In this study we performed karyotype 
analysis and interphase cytogenetics with Y - and 
X-specific probes on 42 B M samples from 18 male 
patients treated with total body irradiation (TBI) and 
C Y or busulphan (BU) and C Y and a transplant from 
their sisters to study possible mixed chimerism. 
Patients and methods 
Patients 
Eighteen male patients who received an allogeneic 
transplant from their HLA-identical MLC-negative 
sisters were studied (Table I ) . All patients but one had 
a malignant blood disease. Some of the results of 
patients 5-7 have been published earlier.2 
The conditioning regimen of patients 1-4, 6-8, 10, 
11, 13 and 18 consisted of C Y 60mg/kg on two 
consecutive days and T B I 2.0 Gy x 6 (total 12 Gy) 
during five days. Patients 5, 12 and 14-17 received B U 
4 mg/kg/day on 4 days and C Y as above. Patient 9 (with 
aplastic anaemia) was conditioned with C Y 50mg/kg 
on four consecutive days. 
A total of 2.3-3.9 x 108 nucleated BM cells/kg 
recipient body weight were transfused at the transplant-
ation. No T cell depletion was done in any case. G V H D 
prophylaxis consisted of C Y A combined with four 
doses of M T X . 6 C Y A was given as continuous iv 
infusion at a dose of 3 mg/kg/day for 2 weeks, and 
thereafter per os for 1 year 1-4 mg/kg/day depending 
on side-effects and blood concentrations. The engraft-
ment was uncomplicated in all patients. Seven patients 
developed acute G V H D (five grade I I , one grade III 
and one grade IV; Table I ) . Four of these seven 
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Table I Patient and control characteristics and outcome of the BMT 
Patients Diagnosis Karyotype in BM Status Age/sex Chronic Outcome Cause of death 
at diagnosis at BMT GVHD 
grade 
GVHD (months) 
1 A M L 46XY,9q-/46,XY CRI 36/M I I + Alive, CR(75+) -
2 ALL 51,XY,+X,+4,+4,+14, + 15/46XY CRI 24/M - - Alive, CR(58+) -3 CML 46XY,t(9;22)(q34;qll) CP 32/M - + Alive, CR(44+) -4 MM 46,XY - 38/M — + Died, CR(41) Obstructive pulmonary disease 
5 AML 46,XY,t(5;ll)(q35;pll) CRI 21/M I I + Alive, CR(43+) -
6 AML 46,XY,t(8;21)(q22;q22) CRI 16/M - - Alive, CR(43+) -7 ALL NS CRII 25/M - + Alive, CR(42+) -8 CML 46,XY,t(9;22)(q34;qll) CP 25/M I I - Alive, CR(38+) -
9 AA 46,XY - 24/M I I I + Died, CR(7) Cardiac death? 10 A M L 46,XY CRI 19/M - - Alive, CR(30+) -11 ALL 46,XY CRI 25/M I I + Alive. CR(29+) -
12 AML 46,XY,8p- Prim ref 29/M IV Died, CR(7) Acute GVHD 
13 MM 46,XY - 45/M - - Alive, CR(25 + ) -14 AML 46,XY,t(15;17)(q22;q21)/46,XY CRI 34/M - + Alive, CR(22+) -15 MDS-AML 45,X,-Y/42,X,-Y,4p-,5q-,6p-, 
-7,llp+,-16,17p+,10q+,-19, 
20q-,+mar,+mar/44,+r,inc/46,XY 
Prim ref 45/M Died (4) Relapse 
16 AML 46,XY CRI 48/M - - Alive, CR(10+) -17 ALL 46,XY CRI 45/M - - Alive, CR(9+) -18 CML 46,XY,t(9;22)(q34;qll) CP 42/M I I - Alive, CR(7+) -
Controls 
19-28 
29-39 
40 
41 
42 
Healthy 46,XY 
Healthy 46,XX 
ALL 48-50,XX, +4,+8,+F,+G/46,XX 
Myeloma 46,XX 
CML 46,XX,t(9;22)(q34;qll) 
33-68/M 
20-78/F 
29/F 
40/F 
27/F 
A A = aplastic anaemia; CP = chronic phase; F = female; inc = incomplete karyotype; M = male; MDS-AML = A M L transformed from 
myelodysplastic syndrome; mar = marker chromosome; MM = multiple myeloma; NS = not studied; prim ref = primarily refractory; r = ring 
chromosome 
patients progressed to chronic G V H D . Four other 
patients developed chronic G V H D without any clinical 
signs of preceding acute G V H D . Four patients died 
during the study (Table I) . 
Karyotype analysis 
Karyotype analyses were performed either on un-
stimulated B M cells from direct cultures or cells 
cultured for 24-48 h as described earlier.3 The chromo-
some preparations were made using standard tech-
niques and examined after trypsin-Giemsa banding.7 
Approximately 20 metaphases were analysed per sam-
ple. 
Interphase cytogenetic analysis 
Interphase cytogenetic studies with Y - and X-specific 
probes were performed on direct B M smears or 
conventional cytogenetic slides prepared as described 
above. 
DNA probes. For single-target NISH and double-
target two-colour F I S H , human Y - and X-specific 
D N A probes were used. The probes recognizing the 
heterochromatic region of the long arm of the Y 
chromosome were pY431 (a gift from K. Smith, School 
of Medicine, The Johns Hopkins University, Balti-
more, MD, U S A ) , and pHY2.1. 8 The X chromosome 
was identified by using the p X B R probe9 which 
identifies the centromeric region of the X chromosome. 
The probes were labelled by standard nick-translation 
with biotin-ll-dUTP (Sigma) or with digoxigenin-ll-
dUTP (Boehringer Mannheim, Germany). 
NISH. BM smears or conventional cytogenetic BM 
preparations from the 18 patients were investigated 
after the B M T by NISH with the biotinylated Y-specific 
probe, pY431. Six patients were also analyzed before 
the BMT. 
Before hybridization the previously stained smears 
were refixed for 30 min in acetic acid-methanol (1/3). If 
hybridization were detected by employing peroxidase 
enzyme, all B M preparations were incubated for 30 min 
in methanol containing 3% (v/v) hydrogen peroxide 
before hybridization.10 The smears were further incu-
bated in ethanol and xylene. 1 0 The conventional 
preparations were treated with pepsin1 1 (0.01-
0.1 mg/ml in 0.01 N HCl; Sigma, St. Louis, MO, USA) 
to remove the cytoplasm. A post-fixation step with 1% 
formaldehyde in PBS containing 50 mM MgCl 2 was 
included in some of the experiments to improve the 
morphology of the cells. 1 2 The NISH was carried out as 
described earlier. 1 0 The signals were detected by 
indirect immunoperoxidase detection system using 
diaminobenzidine ( D A B ; Sigma) as substrate.14 Cells 
were evaluated with a phase-contrast microscope. 
Two-color FISH. B M samples from three patients 
(16-18) were also studied by two-colour F I S H using X-
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and Y-specific D N A probes simultaneously. Hybridiza-
tion conditions were as described earlier. 1 5 The bio-
tinylated X-specific and digoxigenin-labelled Y-specific 
probes were detected simultaneously by the indirect 
immunofluorescence method. Three subsequent steps 
were performed: the first layer contained monoclonal 
mouse anti-digoxin antibody (1:500; Sigma) and 
TRITC-conjugated avidin (1:1000; Vector) in 4 x SSC, 
0.05% Tween-20; the second layer, FITC-conjugated 
sheep anti-mouse antibody (1:200; Sigma) and goat 
anti-avidin-biotin (1:200; Vector Laboratories, Bur-
lingame, C A , U S A ) , and the third layer, FITC-conjug-
ated donkey anti-sheep antibody (1:200; Sigma) and 
TRITC-conjugated avidin (1:1000; Vector). Cells were 
evaluated with a Zeiss Axiophot equipped with epi-
fluorescence. 
Controls. Direct BM smears and conventional B M 
preparations from 10 healthy males, eight healthy 
females and three female patients (40-42) who had 
received a marrow graft from a female donor were 
pre-treated and hybridized simultaneously with the 
patient's slides. Also conventional chromosome pre-
parations prepared from blood samples from the 
healthy donors were included in interphase cytogenetic 
studies as controls. 
Evaluation of the signals. Hybridization studies were 
carried out in a blind fashion. Only non-overlapping 
interphase cells with good morphology were analysed. 
Results 
Karyotype analysis 
A total of 42 patient samples from the 18 patients 
post-BMT were analyzed by karyotype and interphase 
cytogenetic analyses. Karyotype analyses showed no 
residual male host cells at any time point studied in 
patients who remained in clinical remission (17 of 18) 
(Table II ) . Only female cells with a karyotype of 46,XX 
were seen. One patient relapsed during the investiga-
tion period (patient 15). In this patient, at the onset of 
relapse, karyotype analysis showed host cells with one 
of the same clonal abnormalities (45, X , - Y ; 2 out of 20 
metaphases studied) which had been detected at the 
time of diagnosis (Table I) . 
Interphase cytogenetic analysis 
Controls. Hybridizations of the B M smears from five 
healthy male donors showed that, on the average, 96% 
(range 94-98%) of the interphase cells showed a 
Y-specific signal (Figure 1A). Approximately 1000 cells 
per sample were scored. In B M smears from three 
healthy females 0.1% of the cells in one smear showed 
a Y-specific signal but no Y-specific cells were found in 
the other two. In B M smears from the three female 
B M T recipients there were no Y chromosome-positive 
cells. Approximately 800 cells were analyzed per 
sample. Analyses of conventional cytogenetic prepara-
tions from five healthy male donors showed that, on the 
average, 97% (range 95-99%) of the approximately 
1000 cells per sample analyzed were Y-specific. Ana-
lyses of conventional cytogenetic preparations from 
five female donors showed one Y chromosome-positive 
cell in one sample. Approximately 800 cells were 
analyzed per sample. Two-colour F I S H with the 
biotinylated X-specific probe and digoxigenin-labelled 
Y-specific probe on two male B M and blood samples 
studied revealed that 84-92% of the cells (approxi-
mately 200 cells analyzed per sample) showed an X-
and Y-specific signal simultaneously (Figure I B ) . X Y -
specific cells were not detected in the two control 
female blood samples analyzed. 
B M samples from two female donors showed that 
approximately 97% (range 96-97%) of the interphase 
cells showed two signals after F I S H with the X-specific 
probe pXBR325.200 interphase cells per sample were 
scored. 
Patients. In six patients interphase cytogenetic analy-
sis of B M aspirate with the biotinylated Y-specific 
probe pY431 was performed before BMT. Hybridiza-
tions on B M smears from patients 12, 13, 16-18 with a 
normal sex chromosome constitution (Table I ) , showed 
a clear hybridization signal in approximately 95% 
Table II Proportion of residual male host cells in BM samples of the patients in continuous remission post-BMP 
Months Mean proportion of Y chromosome-specific cells (range) 
post-BMT 
Interphase cytogenetics Karyotype analysis 
Smears No. of patients Conventional cytogenetic No. of patients Host cells No.of patients 
studied preparations studied studied 
1 5.3(1.2-13.6) 4 3.2(1.4-6.3) 3 0 7 
2 4.1 (0.7-5.4) 5 1.1 (0-2.4) 5 0 9 
4 1.4(0-3.3) 4 0.6(0.1-2.0) 7 0 8 
8 6.2(5.5-7.2) 3 0.4(0.3-0.5) 2 0 3 
12 5.4(3.1-9.4) 3 0.5(0-0.9) 3 0 5 
24 1.4(0.5-3.3) 5 0.3(0-0.6) 2 0 6 
36 2.3(0.8-3.8) 2 0 1 0 2 
48 0 1 - - 0 1 
60 1.3 1 0 1 0 1 
aData do not include patient 15 who relapsed at 2 months post-BMT 
282 M . WESSMAN et al. 
B C 
Figure 1 Single-target NISH (A) and double-target two-color FISH (B and C) on interphase nuclei from BM aspirates. (A) Biotinylated Y 
chromosome-specific DNA probe pY431 hybridized to BM cells of a control male. Hybridization was detected by indirect immunocytochemical 
procedure using peroxidase enzyme/DAB. Brown precipitate reveals the Y chromosome in the nuclei. The cells were counterstained lightly with 
Hematoxylin. (B and C) Double-target FISH with the biotinylated X chromosome centromere-specific probe pXBR (avidin-TRITC; red signal) 
and with digoxigenin-labelled Y chromosome-specific probe pHY2.1 (FITC-conjugated antibodies; green signal) to BM cells of a male control 
(B) and of a male patient (C; post-BMT). Arrow points to a residual male cell among donor female cells. Microphotographs (B and C) were 
taken by single exposure through a double band-pass filter from Omega (Brattleboro, VT, USA). 
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(range 88-98%) of the interphase cells studied. 
Hybridizations on cultured BM preparations from 
patients 9, 13 and 17 showed a clear signal in 
approximately 94% (range 93-96%) of the cells ana-
lyzed. Hybidizations on BM smear from patient 15 
showed a Y-specific signal in 69% of the cells studied, 
while 49% of the cells on conventional slides were 
Y-positive. Karyotype analysis of this patient had 
revealed two clones with a missing Y chromosome 
(Table I ) . 
Interphase cytogenetic analysis of the samples from 
BMT patients who were in clinical remission during the 
investigation period (17 of 18) revealed the presence of 
host cells in 16 patients (94%). In eight patients host 
cells were detected at or later than 2 years, up to 5 years 
post-BMT. The proportion of residual male host cells 
analyzed from B M chromosome preparations de-
creased rapidly, reaching the average of 0.7% at 2 
months post-BMT (Table I I ) . Thereafter, the propor-
tion of host cells found was <1% in all but one patient 
(in whom the detection was done with double-target 
two-color NISH). On the smears the proportion of 
residual host cells was higher and more variable in 
comparison with the results recorded from conven-
tional BM chromosome preparations (Table II ) . Of 12 
cases where B M smear and conventional chromosome 
preparation from the same aspirate were studied, in 10 
the proportion of host cells was higher in the smear. At 
least 400 cells per patient sample were analyzed in these 
studies. 
There are 13 of the 16 patients, who were in 
remission at 2 months post-BMT and had host cells 
detected at this time point or later, alive with no 
evidence of disease at 7-78 months after the transplant-
ation. There were no relapses among these patients. 
One of the patients (patient 15) relapsed during the 
study period. At the onset of relapse (at 2 months 
post-BMT) this patient had a Y-specific signal in 28% 
(conventional B M chromosome preparation) to 39% 
(BM smear) of the cells analyzed. 
In samples from patients 16-18 the presence of host 
cells was further confirmed by revealing the X Y -
containing cells with double-target two-color F I S H with 
a biotinylated X- and a digoxigenin-labelled Y-specific 
probe simultaneously. Hybridizations revealed that at 1 
month post-BMT 1.4%, at 4 months post-BMT 2% and 
at 8 months post-BMT 5.5% of the cells in samples 
from patients 18, 16 and 17, respectively, were residual 
host cells containing both X and Y chromosomes. 
Hybridizations on samples from patients 16 and 18 
were performed on conventional chromosome slides 
and in the case of patient 17 on direct BM smear. 
There was no difference in the proportion of host 
cells between patients conditioned with T B I and C Y 
and those who received B U and C Y . 
Discussion 
In this study we found that 16 of 17 male recipients of a 
BMT from a female sibling donor who were in 
continuous remission had residual host cells in the BM 
up to several years post-BMT when studied by inter-
phase cytogenetics using a Y-specific D N A probe. This 
finding was confirmed in three patients by demonstra-
ting XY-containing cells with double-target two-color 
F I S H using X- and Y-specific probes simultaneously. 
These findings are in accordance with the findings of 
other studies using NISH with a Y chromosome-
specific probe. 4 , 5 Karyotype analysis showed no host 
cells. 
The use of interphase nuclei allows rapid examina-
tion of a large number of cells from different cell 
populations. This is an obvious advantage in compari-
son with karyotype analysis as cells that are not 
proliferating can be analyzed. By using simultaneously 
X - and Y-specific probes in follow-up studies of 
sex-mismatched B M T cases, the host origin of the cells 
studied is more reliably revealed than by using Y -
specific probes alone. However, by using these probes 
we were not able to identify the cancer specificity of the 
host cells found. 
The finding of persisting residual host cells was 
without doubt real and not due to technical problems, 
as the sensitivity of our interphase cytogenetic analysis 
with the Y-specific probe was quite high (approxi-
mately 97%), and false positive results were rare 
(<0.02%). The fact that no host cells were found in 
karyotype analysis might be due to the low number of 
metaphases studied (usually 20). A more probable 
reason is that the host cells were not dividing or their 
mitotic index was very low. 
Hybridizations on patient samples revealed differ-
ences between conventional cytogenetic preparations 
and direct B M smears. On conventional cytogenetic 
preparations the proportion of host cells later than 2 
months post-BMT was <1% in all but two samples. 
These findings agree with the interphase cytogenetic 
results of Durnam et al.4 and Przepiorka et al.5 who 
studied 87 and 10 B M T patients, respectively. Three 
out of 87 patients studied by Durnam et al.4 and all 10 
patients studied by Przepiorka et al.5 were treated by 
T-cell depleted BMT. On B M smears the proportion of 
host cells was >3% in about 50% of the smears studied 
at or after 2 months post-BMT. Even at ^2 years after 
the transplantation four of nine patients studied had 
>1% host cells in the smear preparations. As to the 
nature of the residual host cells, it is probable that 
many or all of them are stromal cells. It has been 
demonstrated that host stromal cells persist in the 
marrow irrespective of the time post-transplant.16 ,17 It 
is likely that the proportion of stromal cells is higher in 
direct B M smears than in the conventional cytogenetic 
preparations. This probably accounts for the differ-
ences between the results obtained with these two kinds 
of samples. Studies combining immunophenotyping 
with double-target NISH would reveal the nature of the 
residual recipient cells. 
In our study there were no differences in the 
proportion of host cells in the marrow between patients 
conditioned with T B I and C Y and those who received 
B U and C Y . In three previous studies employing 
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restriction fragment length polymorphism ( R F L P ) , 
15-35% of the recipients of non-T-cell-depleated 
marrow have shown mixed chimerism, and the results 
have been similar in patients conditioned with T B I and 
those who have received B U . 1 8 - 2 0 Thus our results 
agree with these previous results although the sensitiv-
ity of our NISH method is far greater. 
In conclusion, residual host cells are found in the B M 
of BMT recipients in continuous clinical remission even 
years after transplantation. Small numbers of residual 
host cells do not indicate imminent relapse. Most or all 
of the host cells may be of stromal origin. For studying 
the presence of a possible residual host hematopoietic 
cell population with a Y-specific probe, conventional 
cytogenetic preparations are preferable to direct B M 
smears because of probably less contamination by 
stromal cells. However, the presence of stromal cells 
always invalidates to some extent the interpretation of 
the results when using Y-specific probes. Therefore, 
probes which identify cancer-specific abnormalities are 
preferable for studying residual hematopoietic host 
cells. 
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